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Abstract
Platelet-derived growth factor receptors (PDGFRs) have been implicated in a wide array of human malignancies, including
medulloblastoma (MB), the most common brain tumor of childhood. Although significant progress in MB biology and
therapeutics has been achieved during the past decades, MB remains a horrible challenge to the physicians and researchers.
Therefore, novel inhibitors targeting PDGFR signaling pathway may offer great promise for the treatment of MB. In the
present study, we investigated the cytotoxicity and mechanisms of cambogin in Daoy MB cells. Our results show that
cambogin triggers significant S phase cell cycle arrest and apoptosis via down regulation of cyclin A and E, and activation of
caspases. More importantly, further mechanistic studies demonstrated that cambogin inhibits PDGFR signaling in Daoy and
genetically defined mouse embryo fibroblast (MEF) cell lines. These results suggest that cambogin is preferentially cytotoxic
to cells expressing PDGFR. Our findings may provide a novel approach by targeting PDGFR signaling against MB.
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Introduction
Medulloblastoma (MB) is the most common malignant central
nervous system tumor in children, accounting for approximately
20% of all pediatric brain cancers [1,2]. Despite the advances in
understanding its biology, a cure is still elusive. Hence, there is an
urgent need for developing new successful therapeutics in MB.
Multiple lines of evidence showed that platelet-derived growth
factor alpha and beta receptors (PDGFRa and PDGFRb)a r ec o -
expressed in MB and overexpressed in metastastic MB, which is
highly associated with poor clinical outcome [2,3]. In addition,
the PDGFRs downstream mitogen-activated protein kinase
(MAPK) signal transduction pathway is also upregulated in
metastastic MB. Neutralizing antibodies to PDGFRa and MAPK
specific inhibitor U0126 inhibited PDGFA-induced migration
and blocked MAP2K1, MAP2K2 and MAPK1/3 phosphoryla-
tion in a dose-dependent manner [3,4,5]. Imatinib mesylate
(Gleevec) is a successful PDGFR tyrosine kinase inhibitor for the
treatment of some hematological malignant [6], dermatofibro-
sarcoma protuberans, and Kit
+ Gastrointestinal Stromal Tumors
(GIST) [7,8,9,10]. Recent study revealed that imatinib induced
apoptosis and inhibited cell proliferation as well as PDGF-BB-
and serum-mediated migration and invasion in Daoy cells via
blockade activation of PDGFRb, Akt, and ERK [11]. These data
suggest that inhibitors of PDGFRs should therefore be considered
for investigation as possible novel therapeutic strategies against
MB.
Natural products have been a wellspring of drugs and drug
leads for decades and remain a major source for drug discovery.
Some of the constituents from Garcinia species have demon-
strated cytotoxic activity in different cancer cell lines [12,13].
Our previous study has demonstrated that a xanthone derivate
dulxanthone A induces cell cycle arrest and apoptosis via up-
regulation of p53 through mitochondrial pathway in HepG2
cells [14]. Benzophenone derivatives and isoxanthochymol
isolated from Garcinia genus showed significant growth
inhibition and induction of apoptosis in human leukemia,
breast cancer, colon cancer, and liver cancer cell lines as well
[15]. Cambogin was isolated from Garcinia cowa and is an
enantiomer of isoxanthochymol. Therefore, it is of great
interest to examine the cytotoxic effect and mechanisms of
cambogin in MB.
Results
Cambogin induces cytoxicity in MB and various solid
tumor cell lines
To determine the effect of cambogin in cancer cells, we first
tested the cytotoxicity of cambogin in a panel of cancer cell lines
using MTS assay. Our results show that following treatment with
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cytotoxicity was observed in all tested cell lines Daoy (MB), SF-
268 (glioblastoma), SHSY5Y (neuroblastoma), HepG2 (hepato-
ma), and Bel7402 (hepatoma) in a dose-dependent manner
(Fig 1B). Among them, MB cell line Daoy is most sensitive to
cambogin treatment. Importantly, cambogin did not affect the
cell viability of PBMCs from health donors at the comparable
dosage (Fig 1C).
Cambogin blocks cell cycle at S phase in Daoy cells
Many anti-tumor agents act at multiple steps in the cell cycle.
The ability of a compound to affect specific phases of the cell
cycle could provide a clue to its cytostatic or cytotoxic
mechanism of action. Following treatment of Daoy cells with
cambogin at different concentrations, a persistent accumulation
of S phase and apoptotic cells was observed (Fig 2A). In
addition, treatment with cambogin at 5 mMf o r2 4hd r a m a t -
ically inhibited DNA synthesis, which was confirmed by BrdU
incorporation assay. The green signal from BrdU was less than
that in the control (Fig 2B). Consistent with cell cycle arrest at S
phase, cyclin A, and cyclin E were down regulated by cambogin
(Fig 2C).
Cambogin triggers apoptosis in Daoy cells
To determine whether the reduction in viability of cancer cells
by cambogin occurred via induction of apoptosis, we used
Annexin V-FITC/PI double staining to quantify apoptosis in
treated Daoy cells. After treatment with cambogin at 2.5 and
5 mM for 24 h, we observed significant induction of apoptosis
evidenced by the increase of Annexin-V
+PI
-(early apoptosis) and
Annexin-V
+/PI
+(late apoptosis and necrosis) populations (Fig 3A).
The induction of apoptosis may also involve activation of
caspases. In the light of our study, cambogin induced caspase 9
activity and reduced downstream procaspase 3 protein expression.
Furthermore, treatment with cambogin also induced PARP
cleavage and bax/bcl2 ratio (Figs 3B-D).
Cambogin inhibits PDGFRa & b pathway
PDGFR signaling has been implicated in the pathogenesis of
variety of cancer types and therefore it is a rational target for
Figure 1. Cambogin triggers cell death in various cancer cell lines. A. Structure of cambogin; B. Cytotocicity of cambogin in various cancer
cell lines Daoy (MB), SF-268 (glioblastoma), SHSY5Y (neuroblastoma), HepG2 (hepatoma), and Bel7402 (hepatoma) upon treatment for 48 h; and C.
Cell viability of peripheral blood mononuclear cells (PBMC) upon treatment with cambogin for 48 h.
doi:10.1371/journal.pone.0021370.g001
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PDGFR signaling pathway. Our results show that cambogin
decreased the expression of PDGFRa and b and the downstream
p-erk expression in Daoy cells (Fig 4A). To confirm the data in
Daoy cells, we further investigate the influence of cambogin on
PDGFR signaling using a panel of genetically defined MEF cell
lines. Following the treatment of MEF cell line with cambogin at
5 mM for 24 h, significant cell death was observed in PDGFRa
+/+,
PDGFRb
+/+, and PDGFR
a +/+ b+/+ cells. However cambogin did
not markedly affect the viability of PDGFR a
2/2b
2/2 cells
(Figs 4B and C). Furthermore, in agreement with the observation
in Daoy cells, cambogin dramatically suppressed the protein
expression of PDGFRa & b and p-erk, triggered the cleavage of
PARP in PDGFRa
+/+, PDGFRb
+/+, and PDGFRa
+/+ b
+/+ cells
in comparison with PDGFR a
2/2b
2/2 cells.
Materials and Methods
Cell Culture and Drug Treatment
Daoy, SF-268, SHSY5Y, HepG2, and Bel7402 cells (obtained
from ATCC, Manassas, VA) were cultured in RPMI 1640
complete medium supplemented with10% FBS (fetal bovine
serum), 100 units/ml penicillin, 100 mg/ml streptomycin, and
2 mM L-glutamine at 37uC and 5% CO2. Genetically defined
MEF cells (PDGFRa
+/+; PDGFRb
+/+, PDGFRa
+/+ b
+/+ and
PDGFR a
2/2b
2/2 cells) were cultured in DMEM complete
medium [17]. Cells were grown to 70% confluence, trypsinized
with 0.25% trypsin, 2 mM EDTA, and seeded 24 h prior to
treatment in all experiments. Peripheral blood mononuclear cells
(PBMCs) were isolated from normal healthy donors by Ficoll and
cultured with RPMI 1640 complete medium [18].
Cambogin was isolated from stems of Garcino cowa and identified
by comparing the EI-MS, 1H, and 13C NMR data with the
literature [19] and dissolved in DMSO at a concentration of
100 mM then diluted in tissue culture medium and filtered before
use. The concentration of DMSO (0.1%) did not affect the cell
viability.
Cytotoxicity Assay
Cytotoxicity of cambogin in cell line and normal PBMCs was
assessed by MTS (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetra-
zolium bromide; Chemicon International Inc, Temecula, CA) and
CellTiter-Glo (Progema, Madison, WI) assays according to the
manufacturer’s instructions.
Apoptosis and Cell Cycle Analysis
Daoy cells were treated with 2.5 and 5 mM cambogin at
indicated times and followed by flow cytometry analysis. Apoptosis
was quantified using Annexin V-FITC/ propidium iodide
detection kit (BD Biosciences, Clontech, CA) and the data were
analyzed with FACSCalibur (BD Bio- sciences). Cell cycle
distribution was determined by PI staining and the percentage of
cells in different cell cycle phases was calculated by ModFit 3.0
(Verity Software House) [14].
Western Blotting
Following treatment with cambogin at 2.5 and 5 mM for 24 h,
Daoy cells were harvested and lysed in RIPA buffer. Equal
amounts of proteins were subjected to NuPAGE 4-12% Bis-Tris
Gel (Invitrogen, Carlsbad, CA) for electrophoresis and then
transferred onto nitrocellulose membranes (Amersham, Piscat-
Figure 2. Cambogin triggers S phase arrest in Daoy cells via down regulation of cyclin A and E. A. Cambogin induces S phase cell cycle
arrest in Daoy cell line. Daoy cells were treated with cambogin for 48 h and followed by flow cytometry analysis. 1, control cells; 2-3, treatment with
2.5 and 5 mM cambogin, respectively. B. Cambogin inhibits DNA synthesis in Daoy cells using BrdU Incorporation Assay. 1, control Daoy cells; 2, Daoy
cells treatment with cambogin at 5 mM for 24 h. C. Cambogin downregulates cyclin A and E using Western blotting. b-actin was used as internal
loading control.
doi:10.1371/journal.pone.0021370.g002
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PDGFRa, anti-PDGFRb, anti-cyclin A, anti-cyclin E, anti-caspase
3, anti-PARP, anti-Bax, anti-Bcl2, anti-perk, anti-erk and, anti-b-
actin antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
Secondary antibody to IgG conjugated to horseradish peroxidase
was used (Bio-Rad, Hercules, CA). Protein bands were visualized
with the ECL Western blotting detection system (Thermo
Scientific, Rockford, IL) according to the manufacturer’s
instructions.
Caspase Activity Assay
Caspase-9 detection kit (QIA 115, Calbiochem, Darmstadt,
Germany) was used to measure caspase-9 activity in live cells
using fluorescent detection. Daoy cells were seeded in 6-well
plates. Following treatment with vehicle or cambogin at
indicated concentrations for 48 h, cells were harvested and
resuspended with 300 ml medium. About 1 mlo fF I T C - L E H D -
FMK was added to each sample (one as blank) and incubated at
37uC, 5% CO2 for 0.5 h. The samples were centrifuged,
washed and resuspended in 100 ml wash buffer. Cells were then
transferred to a 96-well fluorescent plate and the fluorescence
intensity was measured at Ex. 485 nm and Em. 535 nm. One-
factor ANOVA was used and p,0.05 was considered as
significant.
BrdU Incorporation Assay
Daoy cells were treated with vehicle or cambogin at 5 mM for
24 h, and then cells were incubated with 20 mM bromodeoxyur-
idine (5-bromo-2-deoxyuridine, BrdU) for another 1 h before
fixation with acetone (-20uC) for 10 min. After DNA denaturation
in 2 N HCl at 37uC for 30 min, Daoy cells were blocked with
PBSST for 30 min, followed by incubation with BrdU antibody
(10 ml BrdU-Alexa 488/647 with DAPI 1 ml into 90 ml PBSST) for
1 h at room temperature [20]. Pictures were taken under
fluorescence microscopy.
Discussion
Natural products have made, and continue to make, an
indispensable contribution to the discovery and development of
effective drugs for the treatment of human malignancies. In the
current study, we first investigated the cytotoxicity and the mode
of action of cambogin in MB Daoy cells.
Our results show that combogin triggers significant cell death in
various cancer cell lines and exhibits higher sensitivity in MB Daoy
cells. By contrast, cambogin did not markedly affect the cell
viability of normal PBMCs. This indicates the specific anti-tumor
activity and a favorable therapeutic index of combogin. In
addition, induction of the S phase cell cycle arrest and apoptosis
Figure 3. Cambogin triggers apoptosis in Daoy cells. A. Cambogin induces apoptois in Daoy cells. a-c, Daoy cells treatment with cambogin at
0, 2.5, and 5 mM for 24 h, and then apoptosis was quantified by Annexin V/PI staining. B. Treatment with cambogin at 2.5 and 5 mM for 48 h activates
caspase 9. C. Treatment with cambogin at 2.5 and 5 mM for 48 h altered apoptotic regulatory protein expression. D. Protein expression ratio of Bax/
Bcl2 was calculated by NIH ImageJ with correction using b-actin.
doi:10.1371/journal.pone.0021370.g003
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cytotoxic activities of cambogin-induced Daoy cell death.
Following the treatment of cambogin, Daoy cell cycle was arrested
at S phase and DNA synthesis was prominently inhibited. At the
same time, cyclin A and E, the cyclins that govern cell cycle
progression were down regulated. Furthermore, activation of
caspases and increase of bax/bcl2 ratio contribute to cambogin-
triggered apoptosis in Daoy cells as well.
PDGF receptors and/or ligands are overexpressed in a variety
of cancers [16,21]. In the past decade, a number of inhibitors of
receptor tyrosine kinases (RTKs) whose targets include PDGFR
have emerged as therapeutics with remarkable efficacy in the
treatment of human malignancies [22,23,24,25,26].Two report-
ed studies have shown that PDGFRa-neutralizing antibodies and
siRNA silencing of PDGFRb, respectively, inhibited signaling,
migration, and survival in MB Daoy cells [3,11], indicating that
PDGFRs may be therapeutic targets for MB. Hence, a novel
structure targeting PDGFR pathway might offer great promise
as therapeutics in MB. In this context, it is of particular interest
to examine the influence of cambogin on PDGFR signaling
pathway. Our further mechanistic study on cambogin-induced
apoptosis revealed that cambogin inhibits PDGFR signaling by
down-regulation of the protein expression of both PDGFRa and
b, as well as their downstream p-erk in Daoy cells. To confirm
our data in MB, we utilized PDGFRa
+/+,P D G F R b
+/+,
PDGFRa
+/+ b
+/+, and PDGFR a
2/2b
2/2, a panel of
genetically defined MEF cell lines to examine the influence of
cambogin on PDGFR signaling. Similar to our findings in MB
cells, cambogin showed pronounced killing in PDGFRa
+/+,
PDGFRb
+/+,a n dP D G F R a
+/+ b
+/+ MEF cells, which have
either PDGFRa or PDGFRb signaling transduction, but little
killing in PDGFRa
2/2b
2/2 cells lacking PDGFR signaling.
This indicates that PDGFR containing cells were highly sensitive
to cambogin. Viability of the PDGFR a
2/2b
2/2 cells lacking
PDGFRs may be explained by the phenomenon of ‘‘oncogene
addiction’’ [27]. In addition, cambogin down-regulated either
PDGFR a and/or b and p-erk in PDGFRa
+/+,P D G F R b
+/+,
and PDGFRa
+/+ b
+/+cells. However, p-erk did show dramatic
reduction in PDGFR null cells. Furthermore, cambogin induced
more apoptosis in MEF cell lines with PDGFR signaling
evidenced by dramatically decrease in full length PARP
compared with PDGFR null cells. Overall, these data suggest
that down regulation of PDGFRa and /or PDGFRb could at
least partially explain cambogin-induced apoptosis.
In conclusion, our results demonstrate that cambogin is
preferentially cytotoxic to cells expressing PDGFR. Novel
inhibitors targeting PDGFR signaling pathway could provide an
effective strategy for the treatment of MB.
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Figure 4. Cambogin triggers cell death via preferentially PDGFRs pathway. A. Cambogin down regulated PDGFR signaling in Daoy cells
using Western blotting. B and C. Cambogin induced significant cell death in MEF cell lines with PDGFR signaling compared with PDGFR signaling null
cells. The cell growth was measured by MTT and photograph was taken under the microscope. D. Cambogin down regulates PDGFR signaling
(PDGFRa, PDGFRb, erk, p-erk, and PARP) in genetically defined MEF cell lines using Western blotting (b-actin was used as internal loading control).
Four cell lines (PDGFRa
+/+; PDGFRb
+/+, PDGFRa
+/+ b
+/+ and PDGFR a
2/2b
2/2 cells) were used as indicated.
doi:10.1371/journal.pone.0021370.g004
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